At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Aug 25, 2026 at 06:13 ET
Arcosa filed a DEFA14A supplementing its definitive proxy statement for the pending merger with CRH Americas, Inc. The supplement adds disclosures from financial advisors' analyses and addresses stockholder litigation alleging inadequate disclosures. The merger consideration remains $150.00 per share, and the special meeting is scheduled for September 4, 2026.
- Special meeting to vote on merger with CRH Americas, Inc. set for September 4, 2026.
- Merger consideration: $150.00 per share.
- Two stockholder lawsuits filed in New York Supreme Court alleging inadequate proxy disclosures; company voluntarily supplements proxy statement.
- Supplemental disclosures include detailed financial analyses from Evercore and Goldman Sachs, including net debt of ~$1.026B and ~49.6M fully diluted shares.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access